Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans

Table 3 Performance of the generic and cohort-specific signatures on different warfarin studies

Validation cohort	Signature	R² regression against IWPC residuals	P value of difference from the background^a
EUR validation	EUR, generic	0.2	0.008 (e ^–4)
	EUR, cohort-specific	0.08	0.004 (0.05)
	AA, cohort-specific	0.1	0.004 (0.03)
AA validation	EUR, cohort-specific	0.09	0.0009 (0.02)

The R² coefficient is measured on the IWPC residuals
P values below FDR of 0.05 are bolded
^aBackground computed as random signatures. P values of shuffled signatures in parentheses

ISSN: 1756-994X